obesity glp-1 news today drug october 2025 GLP-1 Agonists Weight Loss Drugs Market Size Report, 2030 Obesity Clinical Trials | Expert
Description
C., & Duca, F
The conversation around GLP-1 drugs needs to go beyond before-and-after photos
Several trials have demonstrated that GLP-1 RAs reduce cardiovascular risk in patients with type 2 diabetes mellitus and ASCVD or high cardiovascular risk and have beneficial effects on cardio-renal outcomes beyond their blood glucose-lowering effects in type 2 diabetes mellitus patients
de Oliveira CN, Bisson GB, Piedade E, Osny FJ
